Ken Welsh has been appointed to the scientific advisory board of Health Discovery Corporation, a biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets. Welsh is currently a professor of clinical genomics at Royal Brompton Hospital and Imperial College in London. He is also a science advisor to the West London Transplant Center, and a visiting professor at Oxford University and the University of Utrecht. He received a BSc, PhD, and DSc from Newcastle University.
Health Discovery Corporation also has named Vladimir Vapnik to its scientific advisory board. Vapnik, who won the Humboldt Research award in 2003, is currently a senior researcher at NEC Research. He has worked for AT&T Bell Laboratories and AT&T Labs-Research.
Syrrx has promoted Jeffrey Stafford to vice president of chemistry. Stafford joined the company in 2002 as senior director of chemistry following an 11-year tenure at Glaxo SmithKline, where he held the position of director of chemistry in oncology. Syrrx said Stafford’s team will primarily concentrate on structure-based, small-molecule lead generation and optimization.
Steadman Harrison has been named senior research director and executive director of research and development at PPD’s Piedmont Research Center for preclinical cancer research. Harrison’s responsibilities will include designing, conducting, and interpreting research studies in the areas of tumor biology, biochemistry, and pharmacology, the company said.
Harrison was previously the executive director of experimental medicine and executive director of business development at EMD Pharmaceuticals (Merck KGaA). He has served on the faculties of the University of Kentucky Center for Toxicology and the University of Alabama at Birmingham, and is currently an adjunct faculty member at Duke University. Harrison holds a PhD in pharmacology from Indiana University.